Open-label, Phase 1 Study to Investigate the Effects of Mild, Moderate, and Severe Renal Function Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of ID-085
Latest Information Update: 25 Nov 2019
Price :
$35 *
At a glance
- Drugs ID-085 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Idorsia Pharmaceuticals
- 20 Nov 2019 Status changed from recruiting to completed.
- 06 May 2019 Status changed from not yet recruiting to recruiting.
- 15 Apr 2019 New trial record